2 results
Approved WMOCompleted
To evaluate the pharmacodynamic (PD) effects of daridorexant 25mg, 50mg, and placebo in the middle-of-the-night.
Approved WMORecruiting
Primary objectives1A. To evaluate the effect of maximal LDL-C reduction by Evolocumab on top of high intensity lipid-lowering therapy , initiated immediately after invasive ACS treatment on functional impairment of non-infarct related artery (non-…